Laru‑zova sustains 12‑month gains

Gene therapy for inherited blindness has a recurring problem — early signals can look exciting, then fade once you wait long enough or test them in a tougher study. That is why the new laru-zova update matters. Beacon Therapeutics said its phase 2 DAWN trial in X-linked retinitis pigmentosa, or XLRP, still showed visual-function gains at 12 months, not just at an earlier interim check. The bigger point is not that this settles the drug’s future. It doesn’t. The point is that the durability signal is still alive as the registrational VISTA trial heads toward a topline readout in the second half of 2026. (ophthalmologytimes.com) ### What is XLRP, exactly? XLRP is a rare inherited retinal disease that usually hits boys and men because the causal mutation sits on the X chromosome. In the RPGR form Beacon is targeting, photoreceptors progressively fail, starting with night vision and peripheral vision and moving toward central vision loss and legal blindness, oft(ophthalmologytimes.com) attention. (beacontx.com) ### What is laru-zova trying to do? Laru-zova — short for laruparetigene zovaparvovec — is an AAV gene therapy. Basically, it uses a viral delivery system to carry a working copy of the RPGRORF15 gene into retinal cells through a one-time subretinal injection. The hope is simple: restore enough RPGR function to help rods and cones work better, or at l(beacontx.com)ies. (beacontx.com) ### Why does the 12-month mark matter so much? Because inherited-retina trials are full of noise. Vision can fluctuate. Small open-label studies can flatter a treatment. So when a signal holds up for a full year, it starts to look less like a blip and more like something biologically real. That still is not proof — DAWN is open-label and small — but it is a more serious test than a 3-month or 6-month pop. (ophthalmologytimes.com) ### What actually improved? The main functional readout Beacon highlighted was low-luminance visual acuity, or LLVA — vision under dim conditions, which is a real problem in XLRP. At 12 months, 50% of high-dose participants gained at least 10 ETDRS letters, and 25% gained at least 15 letters, which is roughly a three-line improvement o(ophthalmologytimes.com)acular sensitivity on microperimetry, which matters because it tests how well the central retina detects light point by point. (ophthalmologytimes.com) ### Was it safe enough? So far, mostly yes — with the usual caveat that subretinal gene therapy is not trivial. The reported ocular adverse events were described as mainly related to surgery and steroid prophylaxis rather than obvious vector toxicity. That is encouraging, but long-term safety still matters here because retinal gene therapy can run into inflammation and procedure-related complications that do not show up cleanly in a short snapshot. (ophthalmologytimes.com) ### How does this connect to VISTA? This is the key bridge. DAWN is not the registrational trial. VISTA is. VISTA is a randomized, controlled, masked global phase 2/3 study in 85 males with RPGR-mutated XLRP, comparing two laru-zova doses against untreated control eyes. It is already fully enrolled, and its primary analysis also leans on LLVA — the same endpoint DAWN is now helping to de-risk. (beacontx.com) ### So should this change care right now? Not really. It should raise confidence, not change practice. Patients still need the VISTA readout before anyone can talk seriously about approval or routine use. But for retinal specialists, inherited-disease clinics, and families tracking the RPGR field, this is one of those updates that keeps a program in the “real contender” bucket rather than the “interesting but fading” one. (ophthalmologytimes.com) ### Bottom line The new result is not that laru-zova works beyond doubt. It is that the vision gains Beacon has been talking about did not disappear by month 12. In a disease with no approved treatment, that is enough to make the coming VISTA data matter a lot more. (ophthalmologytimes.com)